BD Ultra-Fine II Insulin Syringe 0 — Class II medical device recall Z-1244-2023
Ongoing recall by Becton Dickinson & Company, reported 2023-03-22, distributed nationwide. Nonsterile syringe potentially exposing the patient to pathogenic microorganisms and a risk of local infection
| Recall number | Z-1244-2023 |
|---|---|
| Product type | Medical device |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Becton Dickinson & Company, Franklin Lakes, NJ, United States |
| Recall initiated | 2023-02-01 |
| Classified | 2023-03-10 |
| Reported by FDA | 2023-03-22 |
| Distributed | Nationwide (US) |
| Countries outside the US | BS, CA, CL, CO, DO, HK, MX, MY, PA, PE, PH, SV, TH, TW, VN |
| Quantity | 1,472,400 units |
| Reason classes | microbial contamination, sterility |
| Lot numbers | 2010670, 20270531, 2031581, 2052365 |
| Model numbers | 326725 |
Product
BD Ultra-Fine II Insulin Syringe 0.5mL, 8mm, 30G-Insulin Syringes are designed for administering insulin in the treatment of diabetes mellitus. Catalog Number: 326725
Reason for recall
Nonsterile syringe potentially exposing the patient to pathogenic microorganisms and a risk of local infection.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/Z-1244-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.